A Phase 1 Study of Safety and Bioactivity With FG-3019 in Combination With Gemcitabine and Erlotinib for Subjects With Locally Advanced or Metastatic Pancreatic Cancer

Locally Advanced or Metastatic Pancreatic Cancer Clinical Trial

Official title:
A Phase 1 Study of Safety and Bioactivity With FG-3019 in Combination With Gemcitabine and Erlotinib for Subjects With Locally Advanced or Metastatic Pancreatic Cancer

Status Completed

Clinical Trial Summary

Objectives

- Primary: To evaluate the safety and tolerability of FG-3019 in combination with gemcitabine and erlotinib

- Secondary: To evaluate the efficacy and pharmacokinetics of FG-3019 in combination with gemcitabine and erlotinib

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Locally Advanced or Metastatic Pancreatic Cancer
Pancreatic Neoplasms

Clinical Trial Details

NCT number	NCT01181245
Study type	Interventional
Source	FibroGen
Contact
Status	Completed
Phase	Phase 1
Start date	December 2008
Completion date	June 2014

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03579836` - Evaluation of Safety and Efficacy in BEY1107 in Monotherapy Gemcitabine Combination in Patient With Pancreatic Cancer	Phase 1/Phase 2
Enrolling by invitation	`NCT03443492` - SLOG vs mFOLFIRINOX as the First-line Treatment in Locally Advanced Uncresectable or Metastatic Pancreatic Cancer	Phase 2
Completed	`NCT03766295` - Masitinib Plus Gemcitabine in Pancreatic Cancer	Phase 3
Completed	`NCT00651742` - Phase 2 Study of S-1 in Advanced or Metastatic Pancreatic Cancer	Phase 2